(E)-4-((4-(dimethylamino)benzylidene)amino)benzenesulfonamide | 1089307-13-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-4-((4-(dimethylamino)benzylidene)amino)benzenesulfonamide
• CAS: 1089307-13-0
• 化学式: C₁₅H₁₇N₃O₂S
• 分子量: 303.385
• InChiKey: PAQQGWPGFHHBBN-GZTJUZNOSA-N

物化性质

• 熔点：
  216-218 °C
• 沸点：
  518.6±60.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.15
• 重原子数：
  21.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  75.76
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  磺胺 、 对二甲氨基苯甲醛 反应 0.08h， 以65%的产率得到(E)-4-((4-(dimethylamino)benzylidene)amino)benzenesulfonamide
  参考文献：
  名称：

  Selective COX-2 inhibitors. Part 2: Synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides

  摘要：

  Two series of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamide derivatives were designed and synthesized for the evaluation as selective cyclooxygenase-2 (COX-2) inhibitors in a cellular assay using human whole blood (HWB). Extensive structure-activity relationships (SAR) were studied within these series. Several compounds were found to be novel and selective COX-2 inhibitors. Among them, the most potent and selective was 4-(3-carboxy-4-hydroxy-benzylideneamino)benzenesulfonamide (20, LA2135), (IC50'S for COX- 1: 85.13 mu M; COX-2: 0.74 mu M; SI: 114.5), being more active COX-2 selective than celecoxib. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.033

文献信息

• METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS
  申请人：Srivastava Rakesh K.

  公开号：US20080214547A1

  公开（公告）日：2008-09-04

  This invention describes a series of methods and compositions for prevention and treatment of diseases such as cancer. One aspect of the invention describes small molecule-based drugs that can be used to bind to death receptors TRAIL-R1/DR4 and/or TRAIL-R2/DR5 and induce apoptosis in cancer cells, while sparing normal cells. The invention also describes TRAIL Death Receptor Agonists/Activators (DRAs) and their uses, such as the induction of apoptosis through caspase-8 and caspase-3 activation. The present invention also describes the methods of treating cancers, such as breast, prostate, colon, pancreatic, ovarian, lung, and brain cancers, leukemia, lymphoma, multiple myeloma, and mesothelioma, using DRAs either as single-agent treatments, or in combination with other therapies.
• US7897364B2
  申请人：——

  公开号：US7897364B2

  公开（公告）日：2011-03-01
• US7915245B2
  申请人：——

  公开号：US7915245B2

  公开（公告）日：2011-03-29
• Selective COX-2 inhibitors. Part 2: Synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides
  作者：Shwu-Jiuan Lin、Wei-Jern Tsai、Wen-Fei Chiou、Tsang-Hsiung Yang、Li-Ming Yang

  DOI：10.1016/j.bmc.2007.11.033

  日期：2008.3

  Two series of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamide derivatives were designed and synthesized for the evaluation as selective cyclooxygenase-2 (COX-2) inhibitors in a cellular assay using human whole blood (HWB). Extensive structure-activity relationships (SAR) were studied within these series. Several compounds were found to be novel and selective COX-2 inhibitors. Among them, the most potent and selective was 4-(3-carboxy-4-hydroxy-benzylideneamino)benzenesulfonamide (20, LA2135), (IC50'S for COX- 1: 85.13 mu M; COX-2: 0.74 mu M; SI: 114.5), being more active COX-2 selective than celecoxib. (C) 2007 Elsevier Ltd. All rights reserved.